Neogenomics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 27 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.94.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Neogenomics Inc is 6.82, ranking 49 out of 75 in the Healthcare Providers & Services industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 190.17M, representing a year-over-year increase of 10.56%, while its net profit experienced a year-over-year increase of 35.52%.
Key Metrics
The current valuation score of Neogenomics Inc is 7.83, ranking 21 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -8.53, which is -30.42% below the recent high of -5.93 and -251.63% above the recent low of -29.98.
The current earnings forecast score of Neogenomics Inc is 7.00, ranking 45 out of 75 in the Healthcare Providers & Services industry. The average price target is 13.00, with a high of 17.00 and a low of 5.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Neogenomics Inc is 6.34, ranking 58 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 8.95 and the support level at 6.31, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Neogenomics Inc is 10.00, ranking 1 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 103.99%, representing a quarter-over-quarter increase of 5.22%. The largest institutional shareholder is The Vanguard, holding a total of 13.80M shares, representing 10.63% of shares outstanding, with 3.85% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Neogenomics Inc is 6.58, ranking 29 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
